News

Zacks.com on MSN9h
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.
Bernstein Sticks to Their Hold Rating for CVS Health (CVS)
In a report released yesterday, Lance Wilkes from Bernstein maintained a Hold rating on CVS Health, with a price target of $72.00. The company’s shares closed yesterday at $63.80. Wilkes covers the ...